DK3026050T3 - Nyt triazinderivat - Google Patents
Nyt triazinderivat Download PDFInfo
- Publication number
- DK3026050T3 DK3026050T3 DK14828654.5T DK14828654T DK3026050T3 DK 3026050 T3 DK3026050 T3 DK 3026050T3 DK 14828654 T DK14828654 T DK 14828654T DK 3026050 T3 DK3026050 T3 DK 3026050T3
- Authority
- DK
- Denmark
- Prior art keywords
- group
- substituted
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (12)
1. Triazinderivat som vist med følgende formel(I):
(i) hvor R1 er en hydroxymethylgruppe, R2 er et hydrogenatom eller en substitueret eller usubstitueret lavere alkylgruppe, A er et nitrogenatom eller C-R3, R3 er et hydrogenatom, cyanogruppe, en substitueret eller usubstitueret acylgruppe, en substitueret eller usubstitueret sulfonylgruppe, eller en substitueret eller usubstitueret carbamoylgruppe, og R4 er en substitueret eller usubstitueret lavere alkylgruppe, eller en substitueret eller usubstitueret cycloalkylgruppe, eller et farmaceutisk acceptabelt salt deraf; hvor den lavere alkylgruppe er en lineær, forgrenet eller cyklisk alkylgruppe med 1 til 3 carbonatomer, og hvor substituenterne af den substituerede lavere alkylgruppe, den substituerede acylgruppe, den substituerede sulfonylgruppe, den substituerede carbamoylgruppe og den substituerede cycloalkylgruppe er én eller flere substituenter valgt fra et halogenatom, en alkylgruppe, en alkoxygruppe, en aminogruppe, en nitrogruppe, en cyanogruppe, en hydroxygruppe, en alkyl aminogruppe, en carbamoylgruppe, en carboxylgruppe, en formylgruppe, en acetylgruppe, en mesylgruppe, en benzoylgruppe, en acylaminogruppe og en acyloxygruppe.
2. Triazinderivat ifølge krav 1, hvor R4 er en substitueret eller usubstitueret cycloalkylgruppe, eller et farmaceutisk acceptabelt salt deraf.
3. Triazinderivat ifølge krav 2, hvor R4 er en cyclopropylgruppe, eller et farmaceutisk acceptabelt salt deraf.
4. Triazinderivat ifølge krav 1, hvor R2 er en methylgruppe, eller et farmaceutisk acceptabelt salt deraf.
5. Triazinderivat ifølge krav 1, hvor R2 er et hydrogenatom, eller et farmaceutisk acceptabelt salt deraf.
6. Triazinderivat ifølge krav 1, hvor A er et nitrogenatom, eller et farmaceutisk acceptabelt salt deraf.
7. Triazinderivat ifølge krav 1, hvor A er en C-R3, eller et farmaceutisk acceptabelt salt deraf.
8. Triazinderivat ifølge krav 1, hvor triazinderivatet er valgt fra gruppen bestående af :
eller et farmaceutisk acceptabelt salt deraf.
9. Farmaceutisk sammensætning omfattende triazinderivatet ifølge et hvilket som helst af kravene 1 til 8, eller et farmaceutisk acceptabelt salt deraf.
10. Triazinderivat ifølge et hvilket som helst af kravene 1-8, eller et farmaceutisk acceptabelt salt deraf, til anvendelse i terapi.
11. Farmaceutisk sammensætning ifølge krav 9 til anvendelse i en fremgangsmåde til behandling af en sygdom relateret til et unormalt cellerespons gennem en Bruton's tyrosinkinase hos et individ med behov derfor.
12. Farmaceutisk sammensætning til anvendelse ifølge krav 11, hvor sygdommen er valgt fra gruppen bestående af autoimmunsygdomme, inflammatoriske sygdomme, knoglesygdomme, cancer, lymfom, og arthritis.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013155331 | 2013-07-26 | ||
| JP2013187987 | 2013-09-11 | ||
| JP2014073227 | 2014-03-31 | ||
| PCT/JP2014/068752 WO2015012149A1 (ja) | 2013-07-26 | 2014-07-15 | 新規トリアジン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3026050T3 true DK3026050T3 (da) | 2019-02-18 |
Family
ID=52393193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14828654.5T DK3026050T3 (da) | 2013-07-26 | 2014-07-15 | Nyt triazinderivat |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9656995B2 (da) |
| EP (1) | EP3026050B1 (da) |
| JP (1) | JP6156953B2 (da) |
| KR (1) | KR101742550B1 (da) |
| CN (1) | CN105683178B (da) |
| AU (1) | AU2014294225B2 (da) |
| CA (1) | CA2919068C (da) |
| CR (1) | CR20160082A (da) |
| DK (1) | DK3026050T3 (da) |
| ES (1) | ES2699452T3 (da) |
| IL (1) | IL243737B (da) |
| NO (1) | NO20160292A1 (da) |
| PH (1) | PH12016500152A1 (da) |
| SG (1) | SG11201600497VA (da) |
| WO (1) | WO2015012149A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3048102A1 (en) * | 2013-09-20 | 2016-07-27 | Carna Biosciences Inc. | Novel triazine derivative |
| BR112019010617A2 (pt) | 2016-11-25 | 2019-09-17 | Carna Biosciences Inc | derivados de oxoisoquinolina |
| EP4101468A4 (en) * | 2020-02-05 | 2024-02-28 | Carna Biosciences, Inc. | COMPOSITION OF ANTI-CANCER AGENT |
| WO2022034914A1 (ja) * | 2020-08-13 | 2022-02-17 | カルナバイオサイエンス株式会社 | 易溶性固形製剤およびその製法 |
| JPWO2022102715A1 (da) * | 2020-11-13 | 2022-05-19 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101523451B1 (ko) * | 2008-07-02 | 2015-05-27 | 에프. 호프만-라 로슈 아게 | 키나아제 억제제로서의 신규 페닐피라지논 |
| US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| MX349372B (es) | 2011-08-17 | 2017-07-26 | Hoffmann La Roche | Inhibidores de la tirosina-cinasa de bruton. |
| KR101673728B1 (ko) * | 2011-12-09 | 2016-11-07 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
| WO2013133367A1 (ja) | 2012-03-09 | 2013-09-12 | カルナバイオサイエンス株式会社 | 新規トリアジン誘導体 |
| WO2013161848A1 (ja) * | 2012-04-27 | 2013-10-31 | カルナバイオサイエンス株式会社 | 新規１，２，４－トリアジン誘導体 |
-
2014
- 2014-07-15 SG SG11201600497VA patent/SG11201600497VA/en unknown
- 2014-07-15 JP JP2015528238A patent/JP6156953B2/ja active Active
- 2014-07-15 KR KR1020167004910A patent/KR101742550B1/ko active IP Right Grant
- 2014-07-15 US US14/907,396 patent/US9656995B2/en active Active
- 2014-07-15 WO PCT/JP2014/068752 patent/WO2015012149A1/ja active Application Filing
- 2014-07-15 CN CN201480051531.1A patent/CN105683178B/zh active Active
- 2014-07-15 AU AU2014294225A patent/AU2014294225B2/en active Active
- 2014-07-15 ES ES14828654T patent/ES2699452T3/es active Active
- 2014-07-15 CA CA2919068A patent/CA2919068C/en active Active
- 2014-07-15 EP EP14828654.5A patent/EP3026050B1/en active Active
- 2014-07-15 DK DK14828654.5T patent/DK3026050T3/da active
-
2016
- 2016-01-22 PH PH12016500152A patent/PH12016500152A1/en unknown
- 2016-01-24 IL IL243737A patent/IL243737B/en active IP Right Grant
- 2016-02-18 CR CR20160082A patent/CR20160082A/es not_active Application Discontinuation
- 2016-02-19 NO NO20160292A patent/NO20160292A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20160168122A1 (en) | 2016-06-16 |
| JP6156953B2 (ja) | 2017-07-05 |
| AU2014294225B2 (en) | 2017-02-23 |
| EP3026050A1 (en) | 2016-06-01 |
| CN105683178A (zh) | 2016-06-15 |
| IL243737B (en) | 2019-09-26 |
| IL243737A0 (en) | 2016-04-21 |
| KR20160041946A (ko) | 2016-04-18 |
| KR101742550B1 (ko) | 2017-06-01 |
| EP3026050A4 (en) | 2016-12-14 |
| CR20160082A (es) | 2016-06-08 |
| CA2919068C (en) | 2018-03-20 |
| US9656995B2 (en) | 2017-05-23 |
| PH12016500152A1 (en) | 2016-04-25 |
| AU2014294225A1 (en) | 2016-03-03 |
| ES2699452T3 (es) | 2019-02-11 |
| CN105683178B (zh) | 2019-04-12 |
| NO20160292A1 (en) | 2016-02-19 |
| EP3026050B1 (en) | 2018-11-07 |
| WO2015012149A1 (ja) | 2015-01-29 |
| SG11201600497VA (en) | 2016-02-26 |
| CA2919068A1 (en) | 2015-01-29 |
| JPWO2015012149A1 (ja) | 2017-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3026050T3 (da) | Nyt triazinderivat | |
| EP3707126A1 (en) | Ire1 small molecule inhibitors | |
| KR20140131955A (ko) | 신규 트리아진 유도체 | |
| RU2722383C2 (ru) | Производные хромена в качестве ингибиторов фосфоинозитид-3-киназ | |
| US10501466B2 (en) | WDR5 inhibitors and modulators | |
| KR102565546B1 (ko) | 신규 옥소이소퀴놀린 유도체 | |
| US20160207906A1 (en) | Novel 2,6-diaminopyrimidine derivative | |
| CN115724830A (zh) | 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法 | |
| US20160221991A1 (en) | Novel triazine derivative | |
| WO2022152140A1 (zh) | 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途 | |
| RU2772226C2 (ru) | Новые производные оксоизохинолина | |
| TW202237101A (zh) | Ｃｔｌａ－４小分子降解劑及其應用 | |
| CN112209934A (zh) | 含有氮杂螺庚烷的btk抑制剂 | |
| CN113993871A (zh) | 含有5-氮杂螺庚烷的btk抑制剂 |